Fact Meets Function

This study looked at patients who developed methemoglobinemia, a serious blood condition where oxygen transport is impaired, after exposure to certain chemicals and drugs over 10 years in Thailand. The research focused on identifying what caused the condition, how patients presented clinically, and what happened to them. This was a safety study examining harmful effects rather than therapeutic benefits of methylene blue.

This study describes how emergency medical services developed a treatment protocol using methylene blue as an antidote for sodium nitrite poisoning. Sodium nitrite poisoning causes dangerous levels of methemoglobin in the blood, which prevents proper oxygen transport. Methylene blue was used by specialized paramedic teams to reverse this life-threatening condition. This represents a specific emergency medical application rather than a general health supplement use.

An older study found that methylene blue did not discolor breast milk when given to nursing mothers, suggesting it may not pass into milk since the drug is 94% protein bound. However, current safety guidelines still recommend stopping breastfeeding during treatment and for 8 days after based on the drug’s 24-hour half-life. There is no available safety data specifically for oral methylene blue use during breastfeeding.